Protocol
Continuous glucose monitoring (CGM) in non-diabetics
CGM · FreeStyle Libre · glucose sensor · metabolic monitoring · continuous glucose monitor
CGM has strong clinical evidence in diabetes, where it improves glycaemic control and is a regulated therapeutic device. That evidence does not transfer to the non-diabetic longevity use case. In healthy people, the case rests on mechanism (glycaemic variability and post-meal spikes are associated with metabolic risk markers) plus short-term behaviour-change data, not on outcome trials. There are no trials showing that wearing a CGM as a non-diabetic extends healthspan, reduces mortality, or prevents incident diabetes. Normal-range reference data for non-diabetics is also thin, so "spikes" flagged by consumer apps often fall within ordinary physiology, and the interpretive layer (scores, rankings, food grades) is proprietary and unvalidated. The honest read: a real, well-engineered measurement device wrapped in a healthspan narrative its own evidence base does not yet support. Note also that Vively's own material states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact and says nothing about approval status.
At a glance
- Evidence
- Commercial
- Singapore (HSA)
- No HSA position on file
- Australia (TGA)
- Not verified from a TGA source. Abbott's Australian FreeStyle Libre site states the labelled indication is "measuring interstitial fluid glucose levels in people (aged 2+) with diabetes" (FreeStyle Libre 2 Plus / 3 Plus), and for insulin-requiring diabetes aged 4+ for FreeStyle Libre 2 — i.e. non-diabetic wellness use sits outside the labelled indication. The ARTG entry number and the device's formal TGA inclusion status could NOT be confirmed from tga.gov.au (ARTG search unreachable during research), so no claim of TGA registration is made here. Separately, Vively states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact, not an approval fact. Treat regulatory status as unconfirmed pending a direct ARTG lookup.
- Offered at
- 4 clinics
Singapore
Health Sciences Authority
- HSA status
- No position on file
- In our SG set
- Tracked in Singapore
- SG clinics
- 2
Australia
Therapeutic Goods Administration
- TGA status
- Not verified from a TGA source. Abbott's Australian FreeStyle Libre site states the labelled indication is "measuring interstitial fluid glucose levels in people (aged 2+) with diabetes" (FreeStyle Libre 2 Plus / 3 Plus), and for insulin-requiring diabetes aged 4+ for FreeStyle Libre 2 — i.e. non-diabetic wellness use sits outside the labelled indication. The ARTG entry number and the device's formal TGA inclusion status could NOT be confirmed from tga.gov.au (ARTG search unreachable during research), so no claim of TGA registration is made here. Separately, Vively states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact, not an approval fact. Treat regulatory status as unconfirmed pending a direct ARTG lookup.
- In our AU set
- Tracked in Australia
- AU clinics
- 2
Evidence is not approvalAn evidence grade describes how strong the science is. A regulatory status describes whether a body has approved the intervention for an indication. They are different questions, answered separately above.
What it is
Plain-language explainer
A continuous glucose monitor is a small sensor worn on the upper arm that samples glucose in interstitial fluid every few minutes and streams the readings to a phone app. In diabetes care it is a well-established clinical tool. In the longevity market it is sold to people without diabetes as a "metabolic health" instrument, on the claim that seeing your own glucose response to meals, exercise and sleep will drive dietary changes that improve long-term metabolic health.
Categories
Protocol
Offered by
Where variis has verified this protocol (4)
Common questions
- What is Continuous glucose monitoring (CGM) in non-diabetics?
- CGM has strong clinical evidence in diabetes, where it improves glycaemic control and is a regulated therapeutic device. That evidence does not transfer to the non-diabetic longevity use case. In healthy people, the case rests on mechanism (glycaemic variability and post-meal spikes are associated with metabolic risk markers) plus short-term behaviour-change data, not on outcome trials. There are no trials showing that wearing a CGM as a non-diabetic extends healthspan, reduces mortality, or prevents incident diabetes. Normal-range reference data for non-diabetics is also thin, so "spikes" flagged by consumer apps often fall within ordinary physiology, and the interpretive layer (scores, rankings, food grades) is proprietary and unvalidated. The honest read: a real, well-engineered measurement device wrapped in a healthspan narrative its own evidence base does not yet support. Note also that Vively's own material states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact and says nothing about approval status.
- How strong is the evidence for Continuous glucose monitoring (CGM) in non-diabetics?
- Commercial. It is offered and sold, which is a statement about availability, not about efficacy.
- Is Continuous glucose monitoring (CGM) in non-diabetics approved in Singapore?
- variis has no Health Sciences Authority position on file for Continuous glucose monitoring (CGM) in non-diabetics. Absence of a recorded position is not approval.
- Is Continuous glucose monitoring (CGM) in non-diabetics approved in Australia?
- Therapeutic Goods Administration position on record: Not verified from a TGA source. Abbott's Australian FreeStyle Libre site states the labelled indication is "measuring interstitial fluid glucose levels in people (aged 2+) with diabetes" (FreeStyle Libre 2 Plus / 3 Plus), and for insulin-requiring diabetes aged 4+ for FreeStyle Libre 2 — i.e. non-diabetic wellness use sits outside the labelled indication. The ARTG entry number and the device's formal TGA inclusion status could NOT be confirmed from tga.gov.au (ARTG search unreachable during research), so no claim of TGA registration is made here. Separately, Vively states Medicare does not cover CGM for non-diabetic individuals in Australia, which is a reimbursement fact, not an approval fact. Treat regulatory status as unconfirmed pending a direct ARTG lookup.. An evidence grade and a regulatory approval are different questions.
- Which clinics offer Continuous glucose monitoring (CGM) in non-diabetics?
- 4 clinics in the variis directory across Singapore and Australia have Continuous glucose monitoring (CGM) in non-diabetics on record. Each is listed on this page with its own sourced profile.
- What else is Continuous glucose monitoring (CGM) in non-diabetics called?
- Also known as CGM, FreeStyle Libre, glucose sensor, metabolic monitoring, continuous glucose monitor.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- FreeStyle Libre Australia — product indications · Abbott Diabetes Care Australia
- Continuous glucose monitoring (CGM) for optimal metabolic health in non-diabetics · Vively
- Vively continuous glucose monitors (CGM) sensor · Vively
- Medical Tests (lists Body Fat % Test and Dexa Scan Test / bone density test) · Everlab (Australia)
- NOVI Health assessments and add-on scans · NOVI Health
- Flagship programmes — Momentum Virtual · Chi Longevity
Every entity profile on variis is sourced. Not medical advice.